Holen Sie sich die Stockscreener-App
2.71
0.37%
-0.01
Handel nachbörslich:
2.77
0.06
+2.21%
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
Published on: 2026-04-03 00:59:30 - baoquankhu1.vn
Context Therapeutics Shares Gain on FDA Fast Track Designation for Ovarian Cancer Drug - marketscreener.com
Context Therapeutics wins FDA fast-track status (CNTX:NASDAQ) - Seeking Alpha
Context Therapeutics Gains FDA Fast Track for CTIM-76 - tipranks.com
Context Therapeutics' CTIM-76 Wins FDA Fast Track; Phase 1a Interim Data Due June 2026 - TradingView
FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer - Stock Titan
Context Therapeutics Receives FDA Fast Track Designation for CTIM-76 in Platinum-Resistant Ovarian Cancer - Quiver Quantitative
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy - The Manila Times
FDA fast-tracks Context drug for hard-to-treat ovarian cancer - Stock Titan
CNTX Stock Price, Quote & Chart | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
S P Trends: Can Context Therapeutics Inc maintain sales growth2026 Sector Moves & AI Based Trade Execution Alerts - baoquankhu1.vn
Support Test: Will Context Therapeutics Inc stock go up in YEARLayoff News & Fast Entry Momentum Alerts - baoquankhu1.vn
Context Therapeutics (NASDAQ:CNTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Q1 EPS Forecast for Context Therapeutics Lowered by Analyst - MarketBeat
Gains Recap: What makes Context Therapeutics Inc stock attractive todayPortfolio Value Report & Technical Buy Zone Confirmations - baoquankhu1.vn
Insider Sell: Is Context Therapeutics Inc stock risky to hold now2026 Historical Comparison & Real-Time Volume Trigger Notifications - baoquankhu1.vn
HC Wainwright Brokers Reduce Earnings Estimates for CNTX - MarketBeat
Context Therapeutics (NASDAQ:CNTX) and Clearmind Medicine (NASDAQ:CMND) Head-To-Head Contrast - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Context Therapeutics (NASDAQ:CNTX) Given Buy Rating at D. Boral Capital - Defense World
Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from Guggenheim - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Price Target Raised to $7.00 - MarketBeat
Context Therapeutics Reports Full Year 2025 Operating and Financial Results - National Today
According to the latest financial data, biopharmaceutical company Context Therapeutics Inc. (Context Therapeutics) held total cash and cash equivalents of $66 million as of December 31, 2025. - Bitget
Context Therapeutics Highlights Evolving T Cell Engager Pipeline - TipRanks
Context Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings Results - MarketBeat
Context Therapeutics Reports Full Year 2025 Operating And Financial Results - TradingView
Context Therapeutics Inc. Reports Financial Results and Upcoming Milestones for CTIM-76 and CT-95 Trials - Quiver Quantitative
Context updates corporate presentation, flags interim CTIM-76/CT-95/CT-202 milestones; cash runway into mid-2027 - tradingview.com
Context Therapeutics (NASDAQ: CNTX) outlines T‑cell engager trials and cash runway - Stock Titan
Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) EstimateContext Therapeutics (NASDAQ:CNTX) - Benzinga
With $66M left, Context targets 2 cancer trial updates in 2026 - Stock Titan
CNTX: Net loss rose to $36.1M in 2025; $66M cash funds operations into mid-2027, more capital needed - TradingView
Context Therapeutics (NASDAQ: CNTX) advances three T cell engager programs - Stock Titan
Context Therapeutics (NASDAQ:CNTX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Surprises Report: How does Bausch Health Companies Inc perform in inflationary periods2026 Key Lessons & Daily Stock Momentum Reports - baoquankhu1.vn
Context Therapeutics to Present Poster at AACR Annual Meeting - National Today
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 - The Manila Times
Context Therapeutics Announces Poster Presentation at the - GlobeNewswire
Context will show preclinical CT-202 tumor data at April cancer meeting - Stock Titan
Loss Report: Is Context Therapeutics Inc stock risky to hold now2026 Dividend Review & Expert Curated Trade Ideas - baoquankhu1.vn
HR Positive/ HER2 Negative Breast Cancer Clinical Trial - openPR.com
HR Positive/ HER2 Negative Breast Cancer Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart
CNTX PE Ratio & Valuation, Is CNTX Overvalued - Intellectia AI
H.C. Wainwright Maintains Buy on APRE Aprea Therapeutics Inc March 2026 - Meyka
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data - MarketBeat
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - MSN
Context Therapeutics Inc. Files 8-K and Certificate of Correction to Amended and Restated Certificate of Incorporation (March 11, 2026) - Minichart
Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes - TipRanks
Board terms change at Context Therapeutics (NASDAQ: CNTX) after court ruling - Stock Titan
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
Quarterly Earnings: How does Context Therapeutics Inc compare to its peersWeekly Profit Report & Risk Controlled Swing Alerts - baoquankhu1.vn
Context Therapeutics (CNTX) to Release Earnings on Thursday - Defense World
Movement Recap: Can Context Therapeutics Inc stock double in the next yearPortfolio Update Report & Stock Market Timing Techniques - baoquankhu1.vn
HER2-Negative Metastatic Breast Cancer Market Expected - openPR.com
HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene - StreetInsider
Context Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
ADXN.SW Addex Therapeutics Ltd (SIX) 09 Mar 2026: Earnings due; liquidity and forecast to watch - Meyka
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):